<- Go Home
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Market Cap
$179.2M
Volume
91.7K
Cash and Equivalents
$4.3M
EBITDA
-$30.7M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$1.8M
Profit Margin
15.46%
52 Week High
$20.03
52 Week Low
$12.52
Dividend
N/A
Price / Book Value
5.03
Price / Earnings
-6.18
Price / Tangible Book Value
5.03
Enterprise Value
$152.5M
Enterprise Value / EBITDA
-5.10
Operating Income
-$31.8M
Return on Equity
72.37%
Return on Assets
-28.59
Cash and Short Term Investments
$35.3M
Debt
$8.6M
Equity
$35.6M
Revenue
$11.9M
Unlevered FCF
-$29.0M
Sector
Pharmaceuticals
Category
N/A